There has been a lot of recent discussion about the potential role of patient preference (PP) data in support of reimbursement decisions. In January 2020, the National Institute for Health and Care Excellence (NICE) published a paper that provided more detail on the use of patient preference data. They emphasised their perspective on the importance of PP data and clarified how this can be used by their committees. This article summarizes the key takeaways from NICE’s publication and what this means for sponsors’ evidence generation strategies.
You are here: / / Patient Preference Studies in HTA Decision Making: A NICE to Have?